Limits...
Decreased Circulating Levels of APRIL: Questioning Its Role in Diabetes.

Carvalho-Santos A, Ribeiro-Alves M, Cardoso-Weide LC, Nunes J, Kuhnert LR, Xavier AR, Cunha S, Hahne M, Villa-Verde DM, Carvalho-Pinto CE - PLoS ONE (2015)

Bottom Line: Our data showed a decrease in serum APRIL levels in T1D patients when compared with healthy individuals.The same pattern was observed in the group of T2D patients when compared with the control.The decrease of serum APRIL levels in diabetic patients suggests that this cytokine has a role in T1D and T2D.

View Article: PubMed Central - PubMed

Affiliation: Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Manguinhos, Rio de Janeiro, Brazil.

ABSTRACT
Diabetes mellitus is a chronic disease that affects over 382 million people worldwide. Type-1 Diabetes (T1D) is classified as an autoimmune disease that results from pancreatic β-cell destruction and insulin deficiency. Type-2 Diabetes (T2D) is characterized principally by insulin resistance in target tissues followed by decreased insulin production due to β-cell failure. It is challenging to identify immunological markers such as inflammatory molecules that are triggered in response to changes during the pathogenesis of diabetes. APRIL is an important member of the TNF family and has been linked to chronic inflammatory processes of various diseases since its discovery in 1998. Therefore, this study aimed to evaluate APRIL serum levels in T1D and T2D. For this, we used the ELISA assay to measure serum APRIL levels of 33 T1D and 30 T2D patients, and non-diabetic subjects as control group. Our data showed a decrease in serum APRIL levels in T1D patients when compared with healthy individuals. The same pattern was observed in the group of T2D patients when compared with the control. The decrease of serum APRIL levels in diabetic patients suggests that this cytokine has a role in T1D and T2D. Diabetes is already considered as an inflammatory condition with different cytokines being implicated in its physiopathology. Our data suggest that APRIL can be considered as a potential modulating cytokine in the inflammatory process of diabetes.

No MeSH data available.


Related in: MedlinePlus

The fasting glucose (FG) levels are weakly negatively correlated with APRIL serum levels in diabetic patients.Log-Normalized (base = 2) APRIL serum levels (ng/mL) corrected by the square-root of age (confounder) and Log-Fasting Glucose mg/dL (base = 2) of control group (black squares; n = 57), T1D patients (black circles; n = 33), and T2D patients (black triangles; n = 30) quantified by ELISA (y-axis, A) are only weakly negatively correlated (rho = -0.278; p-value = 0.0264). Glycated hemoglobin (HbA1c) mmol/mol (base = 2) of the same groups (y-axis, B) are not correlated with APRIL serum levels (rho = -0.111; p-value = 0.4419).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4607466&req=5

pone.0140150.g002: The fasting glucose (FG) levels are weakly negatively correlated with APRIL serum levels in diabetic patients.Log-Normalized (base = 2) APRIL serum levels (ng/mL) corrected by the square-root of age (confounder) and Log-Fasting Glucose mg/dL (base = 2) of control group (black squares; n = 57), T1D patients (black circles; n = 33), and T2D patients (black triangles; n = 30) quantified by ELISA (y-axis, A) are only weakly negatively correlated (rho = -0.278; p-value = 0.0264). Glycated hemoglobin (HbA1c) mmol/mol (base = 2) of the same groups (y-axis, B) are not correlated with APRIL serum levels (rho = -0.111; p-value = 0.4419).

Mentions: The crucial criterion for diabetes classification used by the Endocrinology Service of Medicine School (UFF) is fasting glucose level. Our data indicated that serum APRIL levels in T1D and T2D patients were only weakly negatively correlated with fasting glucose (FG), rho = -0.278; p = 0.0264 (Fig 2A). No correlation was found between glycated hemoglobin (HbA1c) and APRIL serum levels rho = -0.111; p-value = 0.4419, in both T1D and T2D patients (Fig 2B). It is noteworthy that glycated hemoglobin is considered as an accurate index of long-term blood glucose regulation, and according with Diabetics Control and Complications Trial can be responsible for cardiovascular complications.


Decreased Circulating Levels of APRIL: Questioning Its Role in Diabetes.

Carvalho-Santos A, Ribeiro-Alves M, Cardoso-Weide LC, Nunes J, Kuhnert LR, Xavier AR, Cunha S, Hahne M, Villa-Verde DM, Carvalho-Pinto CE - PLoS ONE (2015)

The fasting glucose (FG) levels are weakly negatively correlated with APRIL serum levels in diabetic patients.Log-Normalized (base = 2) APRIL serum levels (ng/mL) corrected by the square-root of age (confounder) and Log-Fasting Glucose mg/dL (base = 2) of control group (black squares; n = 57), T1D patients (black circles; n = 33), and T2D patients (black triangles; n = 30) quantified by ELISA (y-axis, A) are only weakly negatively correlated (rho = -0.278; p-value = 0.0264). Glycated hemoglobin (HbA1c) mmol/mol (base = 2) of the same groups (y-axis, B) are not correlated with APRIL serum levels (rho = -0.111; p-value = 0.4419).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4607466&req=5

pone.0140150.g002: The fasting glucose (FG) levels are weakly negatively correlated with APRIL serum levels in diabetic patients.Log-Normalized (base = 2) APRIL serum levels (ng/mL) corrected by the square-root of age (confounder) and Log-Fasting Glucose mg/dL (base = 2) of control group (black squares; n = 57), T1D patients (black circles; n = 33), and T2D patients (black triangles; n = 30) quantified by ELISA (y-axis, A) are only weakly negatively correlated (rho = -0.278; p-value = 0.0264). Glycated hemoglobin (HbA1c) mmol/mol (base = 2) of the same groups (y-axis, B) are not correlated with APRIL serum levels (rho = -0.111; p-value = 0.4419).
Mentions: The crucial criterion for diabetes classification used by the Endocrinology Service of Medicine School (UFF) is fasting glucose level. Our data indicated that serum APRIL levels in T1D and T2D patients were only weakly negatively correlated with fasting glucose (FG), rho = -0.278; p = 0.0264 (Fig 2A). No correlation was found between glycated hemoglobin (HbA1c) and APRIL serum levels rho = -0.111; p-value = 0.4419, in both T1D and T2D patients (Fig 2B). It is noteworthy that glycated hemoglobin is considered as an accurate index of long-term blood glucose regulation, and according with Diabetics Control and Complications Trial can be responsible for cardiovascular complications.

Bottom Line: Our data showed a decrease in serum APRIL levels in T1D patients when compared with healthy individuals.The same pattern was observed in the group of T2D patients when compared with the control.The decrease of serum APRIL levels in diabetic patients suggests that this cytokine has a role in T1D and T2D.

View Article: PubMed Central - PubMed

Affiliation: Laboratory on Thymus Research, Oswaldo Cruz Institute, Fiocruz, Manguinhos, Rio de Janeiro, Brazil.

ABSTRACT
Diabetes mellitus is a chronic disease that affects over 382 million people worldwide. Type-1 Diabetes (T1D) is classified as an autoimmune disease that results from pancreatic β-cell destruction and insulin deficiency. Type-2 Diabetes (T2D) is characterized principally by insulin resistance in target tissues followed by decreased insulin production due to β-cell failure. It is challenging to identify immunological markers such as inflammatory molecules that are triggered in response to changes during the pathogenesis of diabetes. APRIL is an important member of the TNF family and has been linked to chronic inflammatory processes of various diseases since its discovery in 1998. Therefore, this study aimed to evaluate APRIL serum levels in T1D and T2D. For this, we used the ELISA assay to measure serum APRIL levels of 33 T1D and 30 T2D patients, and non-diabetic subjects as control group. Our data showed a decrease in serum APRIL levels in T1D patients when compared with healthy individuals. The same pattern was observed in the group of T2D patients when compared with the control. The decrease of serum APRIL levels in diabetic patients suggests that this cytokine has a role in T1D and T2D. Diabetes is already considered as an inflammatory condition with different cytokines being implicated in its physiopathology. Our data suggest that APRIL can be considered as a potential modulating cytokine in the inflammatory process of diabetes.

No MeSH data available.


Related in: MedlinePlus